Oncology
PSMA+ mCRPC
Conference Reporter® Podcast: Theranostics and Radiopharmaceuticals in Multimodality Care
Radiopharmaceutical therapy is moving into earlier stages of metastatic prostate cancer care, creating new questions about patient selection, sequencing, dosing, and integration with external beam radiation. Today’s podcast features a discussion with Amar U. Kishan, MD, on key findings on lutetium-177 prostate-specific membrane antigen therapy, radium-223, and SBRT, based on educational sessions and research presented at the 2026 ASTRO Annual Meeting.
Following these presentations, featured expert Amar U. Kishan, MD, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Clinical perspectives from Dr Kishan on these findings are presented here.
Gillessen S, Gallardo E, Choudhury A, et al. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. Ann Oncol. 2026;37(5):736-742. doi:10.1016/j.annonc.2026.02.009
Kishan AU, Valle LF, Wilhalme H, et al. 177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study. J Clin Oncol. 2025;43(36):3812-3821. doi:10.1200/JCO-25-01553
Morris Z. Harnessing the tumor microenvironment and abscopal effects of RPTs [session: EDU 57 – The biology of radiopharmaceuticals (RPTs): beyond the physical properties]. Session presented at: 2026 American Society for Radiation Oncology Annual Meeting; September 26-30, 2026; Boston, MA.
Tagawa ST, Sartor O, Piulats JM, et al; PSMAddition Investigators. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026;408(10557):793-807. doi:10.1016/S0140-6736(26)01092-5
Taplin ME, Riaz IB, Rumble RB, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO living guideline, version 2026.1. J Clin Oncol. 2026;44(6):e1-e14. doi:10.1200/JCO-25-02693
Yu ED, Romero T, Rettig M, et al. Eugonadal progression-free survival following intensification of metastasis-directed stereotactic body radiotherapy with radioligand therapy or androgen annihilation therapy: a comparison of two phase II trials [abstract 1217] [session: QP 37 – From detection to re-treatment: managing radiorecurrent prostate cancer]. Abstract presented at: 2026 American Society for Radiation Oncology Annual Meeting; September 26-30, 2026; Boston, MA.
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society for Radiation Oncology.
